Clinical Trial Update: A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments [Phase 3]

View source ↗

Summary

Phase 3 trial of ustekinumab in active polymyositis and dermatomyositis was terminated, with results posted on May 13, 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatomyositis
• Polymyositis

Drugs mentioned

• Stelara (ustekinumab)

Snippet

Sponsor: Janssen Pharmaceutical K.K. | Conditions: Polymyositis, Dermatomyositis | Phase 3 | Status: TERMINATED | Results posted: 2024-05-13